SCHEMBL19785029

SCHEMBL19785029

N#Cc1cc(NC(=O)Oc2ccccc2)ccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.56
ALDH1A1 P00352 7/20 0.52
MAPT P10636 4/20 0.52
KDM4E B2RXH2 2/20 0.52
RAD51 Q06609 2/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.49
FAAH O00519 1/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
THRB P10828 1/20 0.48
GFER P55789 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
GAA P10253 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
BRD4 O60885 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29454265 1.00 GRM4 (0.56) GRM4ALDH1A1MAPTKDM4ERAD51
SCHEMBL16728648 0.89 ALDH1A1 (0.52) GRM4ALDH1A1MAPTKDM4ERAD51
SCHEMBL28282029 0.86 ALDH1A1 (0.51) GRM4ALDH1A1MAPTKDM4ERAD51
SCHEMBL29739534 0.84 ALDH1A1 (0.55) ALDH1A1MAPTKDM4ERAD51CYP1A2
SCHEMBL13631869 0.84 ALDH1A1 (0.52) ALDH1A1MAPTKDM4ERAD51CYP1A2
SCHEMBL30023038 0.84 POLB (0.59) GRM4ALDH1A1MAPTKDM4ERAD51
SCHEMBL9488977 0.84 POLB (0.59) GRM4ALDH1A1MAPTKDM4ERAD51
SCHEMBL3983141 0.83 ALDH1A1 (0.60) ALDH1A1MAPTKDM4ERAD51CYP1A2
SCHEMBL22727083 0.82 GRM4 (0.64) GRM4ALDH1A1
SCHEMBL3008351 0.81 GRM4 (0.56) GRM4ALDH1A1MAPTCYP1A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976617-B1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2025-04-23 EP disclosed
US-20250009742-A1 NOVEL CAPSID ASSEMBLY INHIBITORS META-IMMUNE, INC. (KR) 2025-01-09 US disclosed
CN-113923988-B Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same 爱彼特生物制药公司 2024-12-13 CN disclosed
EP-4416142-A1 NOVEL CAPSID ASSEMBLY INHIBITORS AM Sciences Inc (KR) 2024-08-21 EP disclosed
CN-118103363-A Novel capsid assembly inhibitor 南韩商AM科学股份有限公司 2024-05-28 CN disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
WO-2023063697-A1 NOVEL CAPSID ASSEMBLY INHIBITORS AM SCIENCES INC (KR) 2023-04-20 WO disclosed
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-02-09 US disclosed
US-11572372-B2 Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds MEDSHINE DISCOVERY INC. (CN) 2023-02-07 US disclosed
CN-115087486-A Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof 爱彼特生物制药公司 2022-09-20 CN disclosed
US-20200377517-A1 ANTI-HBVTETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS MEDSHINE DISCOVERY INC. (CN) 2020-12-03 US disclosed
WO-2020243153-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2020-12-03 WO disclosed
EP-3712139-A1 ANTI-HBV TETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2020-09-23 EP disclosed
US-10683299-B2 Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases HOFFMANN LA ROCHE INC. (US) 2020-06-16 US disclosed
EP-3484886-B1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES HOFFMANN LA ROCHE (CH) 2020-03-04 EP disclosed
US-20190248792-A1 NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES HOFFMANN-LA ROCHE INC. (US) 2019-08-15 US disclosed
CN-109843892-A Dislike diazepine ketone derivatives and its purposes in treatment hepatitis B infection 诺维拉治疗公司 2019-06-04 CN disclosed
CN-109641896-A DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS 诺维拉治疗公司 2019-04-16 CN disclosed
CN-109476668-A For treating 6,7- dihydro -4H- pyrazolo [1,5-a] pyrazine and 6,7- dihydro -4H- triazol [1,5-a] pyrazine compound of infectious diseases 豪夫迈·罗氏有限公司 2019-03-15 CN disclosed
WO-2018011163-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248792-A1 NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES CYP3A5, RRP15, HAVCR2 GRM4 3415/4885ALDH1A1 1006/4885MAPT 3240/4885
US-10683299-B2 Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases CYP3A5, RRP15, QDPR GRM4 3459/4885ALDH1A1 914/4885MAPT 3266/4885
US-11572372-B2 Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds HAVCR2, HCCS, CD4 GRM4 2578/4885ALDH1A1 3483/4885MAPT 3654/4885
US-20250009742-A1 NOVEL CAPSID ASSEMBLY INHIBITORS ZC3HAV1, ZC3HAV1L, MAVS GRM4 3207/4885ALDH1A1 4357/4885MAPT 474/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 GRM4 3647/4885ALDH1A1 3447/4885MAPT 484/4885
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HMBS, AHCY GRM4 4030/4885ALDH1A1 2620/4885MAPT 4056/4885
US-20200377517-A1 ANTI-HBVTETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS HAVCR2, HCCS, CD4 GRM4 2578/4885ALDH1A1 3483/4885MAPT 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.